FDA’s Expedited Drug Programs: Analysis, Postmarket Monitoring and Industry Guidance

Gary Lawrence (Editor)

Series: Drug Transit and Distribution, Interception and Control
BISAC: MED071000

Clear

$95.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

The Food and Drug Administration (FDA) oversees the safety and effectiveness of drugs sold on the U.S. market. When there is an unmet need for the treatment of a serious condition, FDA may use one or more of its expedited programs, such as fast track and breakthrough therapy designation, which are intended to bring drugs to market more quickly. FDA is also responsible for monitoring the safety of drugs and reporting on those efforts. This book examines the number and types of requests for fast track or breakthrough therapy designation; the number and types of FDA-approved drug applications that used an expedited program; and the extent to which FDA’s data on tracked safety issues and postmarket studies allowed the agency to meet its reporting and oversight responsibilities. (Imprint: Novinka)

Preface

Chapter 1. Drug Safety: FDA Expedites Many Applications, But Data for Postapproval Oversight Need Improvement
United States Government Accountability Office

Chapter 2. Statement of Janet Woodcock, Director, Center for Drug Evaluation and Research, Food and Drug Administration. Hearing on ''21st Century Cures: Incorporating the Patient Perspective''

Chapter 3. Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics
Food and Drug Administration

Index

You have not viewed any product yet.